Karim Sayed
Research Subjects
Karim Sayed has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Koenraad De Boulle
Aalst Dermatology Clinic, Aalst, Belgium
2 shared publications - Wolfgang G. Philipp-Dormston
Hautzentrum Köln (Cologne Dermatology), Köln, Germany; Faculty of Health, University Witten-Herdecke, Witten, Germany
2 shared publications - Ariel Haus
Dr Haus Dermatology London UK
1 shared publication - Catherine Ellen Porter
All Saints Skin Clinic, Darlinghurst, NSW, Australia
1 shared publication - Catherine Stone
The Face Place Medspa, Auckland, New Zealand
1 shared publication - Dario Bertossi
Department of Maxillo Facial Surgery, Head & Neck Department Università degli Studi di Verona Verona Italy
1 shared publication
Latest Publications
- 10 July 2026
- Published by Springer Nature in Aesthetic Plastic Surgery
- Vol. 50 (18) , 7784-7807
Botulinum Toxin A Myths, Evidence, and Global Media Narratives
Introduction Botulinum Neurotoxin A (BoNT-A) is clinically safe and effective, yet public discourse remains saturated with myths. This review investigates how misconceptions are produced and sustained within peer-reviewed literature and traditional media. Methods A narrative synthesis of English-language publications (2000–2024) from PubMed, Scopus, Web of Science (peer-reviewed) and ProQuest, Factiva, LexisNexis (media) was conducted. AI-assisted search, clustering (UMAP–HDBSCAN), and VADER sentiment analysis were integrated. Inter-rater reliability (κ = 0.87–0.94) and AI-human agreement (89.5%) were established. “Botox” is used as a generic term for all BoNT-A products consistent with public and social media discourse. Results Of 513 sources (186 academic, 327 media), myths clustered into eight categories. Media coverage showed strongly negative sentiment (mean − 0.58), while academic literature remained neutral (71% neutral). Safety/toxicity myths were 3.2 times more frequent in media (χ2 = 29.8, p < 0.001). Psychological myths carried a mean sentiment of − 0.61 (Kruskal–Wallis H = 28.4, p < 0.001). Geographic mapping identified misinformation spikes following litigation, celebrity disclosures, and regulatory advisories. Novel myths (e.g. immune suppression, “patchwork ageing”) emerged post-2019 (mean sentiment – 0.69). Conclusion A quantifiable asymmetry exists between scientific evidence and media framing of BoNT-A. Misinformation is culturally embedded, emotionally charged, and event driven. Bridging this gap requires pre-consultation educational tools, scripted clinical responses, and cross-disciplinary media engagement. Level of Evidence IV This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.
- 10 July 2026
- Published by Springer Nature in Aesthetic Plastic Surgery
- Vol. 50 (18) , 7784-7807
Botulinum Toxin A Myths, Evidence, and Global Media Narratives
Introduction Botulinum Neurotoxin A (BoNT-A) is clinically safe and effective, yet public discourse remains saturated with myths. This review investigates how misconceptions are produced and sustained within peer-reviewed literature and traditional media. Methods A narrative synthesis of English-language publications (2000–2024) from PubMed, Scopus, Web of Science (peer-reviewed) and ProQuest, Factiva, LexisNexis (media) was conducted. AI-assisted search, clustering (UMAP–HDBSCAN), and VADER sentiment analysis were integrated. Inter-rater reliability (κ = 0.87–0.94) and AI-human agreement (89.5%) were established. “Botox” is used as a generic term for all BoNT-A products consistent with public and social media discourse. Results Of 513 sources (186 academic, 327 media), myths clustered into eight categories. Media coverage showed strongly negative sentiment (mean − 0.58), while academic literature remained neutral (71% neutral). Safety/toxicity myths were 3.2 times more frequent in media (χ2 = 29.8, p < 0.001). Psychological myths carried a mean sentiment of − 0.61 (Kruskal–Wallis H = 28.4, p < 0.001). Geographic mapping identified misinformation spikes following litigation, celebrity disclosures, and regulatory advisories. Novel myths (e.g. immune suppression, “patchwork ageing”) emerged post-2019 (mean sentiment – 0.69). Conclusion A quantifiable asymmetry exists between scientific evidence and media framing of BoNT-A. Misinformation is culturally embedded, emotionally charged, and event driven. Bridging this gap requires pre-consultation educational tools, scripted clinical responses, and cross-disciplinary media engagement. Level of Evidence IV This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.
- Open Access
- 5 May 2026
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 25 (5) , e70880
International Expert Consensus on Integrated Skincare Active Ingredients for Pretreatment and Posttreatment Use With Medical Aesthetic Procedures to Enhance Skin Benefits
Background: Integrated skincare (ISC) combines dermocosmetics with medical aesthetic procedures to improve outcomes. However, guidance on selecting appropriate active ingredients across different procedure types and phases remains limited. Aims: To provide international guidance on appropriate ISC actives for use with aesthetic procedures. Methods: In a simplified Delphi study, 14 experts evaluated 44 actives for use across four procedure categories (ablative energy‐based, non‐ablative energy‐based, non‐energy‐based procedures with or without skin barrier disruption) at four time points (pretreatment, peri‐treatment, aftercare, and follow‐up ≥ 1 week post‐procedure). The panelists also ranked their top five preferred actives for each procedure category and time point. Results: Ceramides, cholesterol, hyaluronic acid, niacinamide, and peptides were deemed appropriate across all procedure categories and all time points. Azelaic acid, benzoyl peroxide, cysteamine, glycolic acid, hydroquinone, lactic acid, retinoids, and salicylic acid were identified as unsuitable for use on treatment day. Ceramides and hyaluronic acid were highly ranked for pre‐treatment, peri‐treatment and aftercare, while retinoids and ferulic acid were highly ranked for pretreatment and followup. Vitamin C was ranked in the top 5 across all procedure categories and time points, except at pretreatment for non‐energy‐based without skin barrier damage. Conclusions: Safety and tolerability are primary considerations when selecting ISC actives. Ingredients with higher irritation potential, such as retinoids and acids, should be avoided during the healing phase (on treatment day and during short‐term aftercare) due to risk of irritation, as well as post‐inflammatory hyperpigmentation in skin of color.
- 5 May 2026
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 25 (5) , e70880
Open AccessInternational Expert Consensus on Integrated Skincare Active Ingredients for Pretreatment and Posttreatment Use With Medical Aesthetic Procedures to Enhance Skin Benefits
Background: Integrated skincare (ISC) combines dermocosmetics with medical aesthetic procedures to improve outcomes. However, guidance on selecting appropriate active ingredients across different procedure types and phases remains limited. Aims: To provide international guidance on appropriate ISC actives for use with aesthetic procedures. Methods: In a simplified Delphi study, 14 experts evaluated 44 actives for use across four procedure categories (ablative energy‐based, non‐ablative energy‐based, non‐energy‐based procedures with or without skin barrier disruption) at four time points (pretreatment, peri‐treatment, aftercare, and follow‐up ≥ 1 week post‐procedure). The panelists also ranked their top five preferred actives for each procedure category and time point. Results: Ceramides, cholesterol, hyaluronic acid, niacinamide, and peptides were deemed appropriate across all procedure categories and all time points. Azelaic acid, benzoyl peroxide, cysteamine, glycolic acid, hydroquinone, lactic acid, retinoids, and salicylic acid were identified as unsuitable for use on treatment day. Ceramides and hyaluronic acid were highly ranked for pre‐treatment, peri‐treatment and aftercare, while retinoids and ferulic acid were highly ranked for pretreatment and followup. Vitamin C was ranked in the top 5 across all procedure categories and time points, except at pretreatment for non‐energy‐based without skin barrier damage. Conclusions: Safety and tolerability are primary considerations when selecting ISC actives. Ingredients with higher irritation potential, such as retinoids and acids, should be avoided during the healing phase (on treatment day and during short‐term aftercare) due to risk of irritation, as well as post‐inflammatory hyperpigmentation in skin of color.
- Open Access
- 1 February 2025
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 18, 431-441
Prevention and Management of Complications With a Hyaluronic Acid–Calcium Hydroxyapatite Hybrid Injectable
Background: A ready-to-use hyaluronic acid–calcium hydroxyapatite (HA-CaHA) hybrid injectable has a dual mode of action for soft-tissue augmentation. Although previous studies have reported a favorable safety profile for HA-CaHA, there is a need for guidelines and recommendations based on real-world clinical experience for the management of complications associated with HA-CaHA. Purpose: This publication provides guidelines and recommendations for the prevention and management of HA-CaHA–related complications. A case study example, treatment algorithms, and injection techniques are included to illustrate the management of complications. Materials and Methods: On January 25, 2023, 13 European physicians were invited to an advisory board meeting to discuss strategies for optimizing patient care, minimizing adverse events (AEs), and identifying data gaps for the prevention and management of complications with HA-CaHA. Results: The management of a subset of AEs, including skin discoloration and edema, was discussed. Small group workshops also shared management algorithms for late noninflammatory adverse reactions, late inflammatory adverse reactions, localized vascular complications, and retinal vascular complications. Best practices for optimal injection techniques were discussed, and injection-technique protocols were developed for treatment sites. Treatment strategies for HA-CaHA–related complications are considered similar to treatment of those resulting from single-agent fillers, and knowledge of anatomy, aseptic technique, correct injection techniques, and appropriate posttreatment care is emphasized. Conclusion: These recommendations on the management of HA-CaHA–related complications may serve as a reference for the broad range of clinicians using HA-CaHA hybrid injectable for different indications and can help optimize patient outcomes and safety.
- 1 February 2025
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 18, 431-441
Open AccessPrevention and Management of Complications With a Hyaluronic Acid–Calcium Hydroxyapatite Hybrid Injectable
Background: A ready-to-use hyaluronic acid–calcium hydroxyapatite (HA-CaHA) hybrid injectable has a dual mode of action for soft-tissue augmentation. Although previous studies have reported a favorable safety profile for HA-CaHA, there is a need for guidelines and recommendations based on real-world clinical experience for the management of complications associated with HA-CaHA. Purpose: This publication provides guidelines and recommendations for the prevention and management of HA-CaHA–related complications. A case study example, treatment algorithms, and injection techniques are included to illustrate the management of complications. Materials and Methods: On January 25, 2023, 13 European physicians were invited to an advisory board meeting to discuss strategies for optimizing patient care, minimizing adverse events (AEs), and identifying data gaps for the prevention and management of complications with HA-CaHA. Results: The management of a subset of AEs, including skin discoloration and edema, was discussed. Small group workshops also shared management algorithms for late noninflammatory adverse reactions, late inflammatory adverse reactions, localized vascular complications, and retinal vascular complications. Best practices for optimal injection techniques were discussed, and injection-technique protocols were developed for treatment sites. Treatment strategies for HA-CaHA–related complications are considered similar to treatment of those resulting from single-agent fillers, and knowledge of anatomy, aseptic technique, correct injection techniques, and appropriate posttreatment care is emphasized. Conclusion: These recommendations on the management of HA-CaHA–related complications may serve as a reference for the broad range of clinicians using HA-CaHA hybrid injectable for different indications and can help optimize patient outcomes and safety.
- Open Access
- 1 February 2024
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 17, 329-337
The Patient Journey in Facial Aesthetics: Findings from a European Consensus Meeting on Improving the Quality of Life for Patients Receiving Botulinum Toxin Injections
Purpose: Successful treatment of facial lines with botulinum toxin is largely dependent on patient satisfaction; thus, a structured treatment journey that uses patient-reported outcomes (PROs) is helpful for maximizing botulinum toxin results. To develop a patient-centric approach for botulinum toxin injections in facial aesthetics, a group of clinicians met to provide opinions on an optimal treatment journey that uses PROs to quantify treatment benefits on patient quality of life. Patients and Methods: A multidisciplinary panel of 9 clinicians with expertise in facial aesthetic procedures convened for an advisory board that was preceded by and followed up with a structured, multistep consensus discussion. Based on current literature, the panel’s expertise, structured questions, and group discussion, panelists assessed, reconciled, and agreed upon on a patient journey for botulinum toxin treatment in facial aesthetics. Results: Panelists agreed that an optimal patient journey includes screening, assessment, treatment, posttreatment, and follow-up visits. A compact, easy-to-complete, and digital PRO questionnaire should be provided before the visit. During screening, thorough assessments are integral for a successful patient journey because they provide an opportunity to understand treatment goals, address patient concerns, discuss risks and benefits, obtain medication lists/medical history, and take pretreatment photographs. Treatment strategies should include discussing and educating on the approach/choice of botulinum toxin and ensuring patients are comfortable. Posttreatment, clinicians should request intense muscle movements to enhance product uptake and be available to address patient concerns. Finally, during follow-up, PRO questionnaires can be provided to gauge patient satisfaction with treatment, and pretreatment photographs can be provided to allow patients to track their progression. Follow-ups should be scheduled with new patients or those reporting low satisfaction. Conclusion: Establishing a relationship, being aware of the patient’s goals, and developing an individualized care plan allows for a structured, patient-centered treatment journey that promotes positive aesthetic outcomes.
- 1 February 2024
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 17, 329-337
Open AccessThe Patient Journey in Facial Aesthetics: Findings from a European Consensus Meeting on Improving the Quality of Life for Patients Receiving Botulinum Toxin Injections
Purpose: Successful treatment of facial lines with botulinum toxin is largely dependent on patient satisfaction; thus, a structured treatment journey that uses patient-reported outcomes (PROs) is helpful for maximizing botulinum toxin results. To develop a patient-centric approach for botulinum toxin injections in facial aesthetics, a group of clinicians met to provide opinions on an optimal treatment journey that uses PROs to quantify treatment benefits on patient quality of life. Patients and Methods: A multidisciplinary panel of 9 clinicians with expertise in facial aesthetic procedures convened for an advisory board that was preceded by and followed up with a structured, multistep consensus discussion. Based on current literature, the panel’s expertise, structured questions, and group discussion, panelists assessed, reconciled, and agreed upon on a patient journey for botulinum toxin treatment in facial aesthetics. Results: Panelists agreed that an optimal patient journey includes screening, assessment, treatment, posttreatment, and follow-up visits. A compact, easy-to-complete, and digital PRO questionnaire should be provided before the visit. During screening, thorough assessments are integral for a successful patient journey because they provide an opportunity to understand treatment goals, address patient concerns, discuss risks and benefits, obtain medication lists/medical history, and take pretreatment photographs. Treatment strategies should include discussing and educating on the approach/choice of botulinum toxin and ensuring patients are comfortable. Posttreatment, clinicians should request intense muscle movements to enhance product uptake and be available to address patient concerns. Finally, during follow-up, PRO questionnaires can be provided to gauge patient satisfaction with treatment, and pretreatment photographs can be provided to allow patients to track their progression. Follow-ups should be scheduled with new patients or those reporting low satisfaction. Conclusion: Establishing a relationship, being aware of the patient’s goals, and developing an individualized care plan allows for a structured, patient-centered treatment journey that promotes positive aesthetic outcomes.
- Top Cited PapersOpen Access
- 1 August 2021
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 14, 1105-1118
Treating Aging Changes of Facial Anatomical Layers with Hyaluronic Acid Fillers
The aging process affects every anatomical layer of the face. Improved knowledge of how aging occurs in each anatomical layer of the face has helped evolve the facial rejuvenation strategies with HA fillers. Understanding the age-related changes in the anatomical facial layers, including their time of onset and how the changes occur in the different tissue layers, an injector can provide much more targeted and refined HA filler treatments. As fillers’ use has increased, there has been a distinct shift away from procedures lifting the skin and SMAS. We can selectively target the anatomical facial layers with HA fillers for more refined and predictable outcomes. An extensive range of HA filler variants is now available. Each filler type is optimized and designed to be injected into specific tissue planes for the best results. Knowing the predictable aging changes in the different tissue layers of the face is crucial as this guides the optimum filler choice. Working knowledge of the individual characteristics of the numerous HA-based products allows for their effective placement in the correct layer. Familiarity with the correct HA product may also help to minimize the downtime and risk of adverse events.
- 1 August 2021
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 14, 1105-1118
Top Cited PapersOpen AccessTreating Aging Changes of Facial Anatomical Layers with Hyaluronic Acid Fillers
The aging process affects every anatomical layer of the face. Improved knowledge of how aging occurs in each anatomical layer of the face has helped evolve the facial rejuvenation strategies with HA fillers. Understanding the age-related changes in the anatomical facial layers, including their time of onset and how the changes occur in the different tissue layers, an injector can provide much more targeted and refined HA filler treatments. As fillers’ use has increased, there has been a distinct shift away from procedures lifting the skin and SMAS. We can selectively target the anatomical facial layers with HA fillers for more refined and predictable outcomes. An extensive range of HA filler variants is now available. Each filler type is optimized and designed to be injected into specific tissue planes for the best results. Knowing the predictable aging changes in the different tissue layers of the face is crucial as this guides the optimum filler choice. Working knowledge of the individual characteristics of the numerous HA-based products allows for their effective placement in the correct layer. Familiarity with the correct HA product may also help to minimize the downtime and risk of adverse events.